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Abstract
Background: β-lactam resistance in Gram-negative bacteria is a significant clinical problem in the
community, long-term care facilities, and hospitals. In these organisms, β-lactam resistance most
commonly results from the production of β-lactamases. In Gram-negative bacilli, TEM-, SHV-, and
CTX-M-type β-lactamases predominate. Therefore, new and accurate detection methods for these
β-lactamase producing isolates are needed.
Results: E. coli DH10B cells producing SHV-1 β-lactamase and a clinical isolate of K. pneumoniae
producing SHV-5 β-lactamase were rendered membrane permeable, fixed and adhered to poly-L-
lysine coated slides, and stained with purified polyclonal anti-SHV antibodies that were fluorescein
labeled. E. coli DH10B cells without a blaSHV gene were used as a negative control. The procedure
generated a fluorescence signal from those slides containing cells expressing SHV β-lactamase that
was sufficient for direct imaging.
Conclusion: We developed a rapid and accurate method of visualizing the SHV family of enzymes
in clinical samples containing Gram-negative bacilli using a fluorescein-labeled polyclonal antibody.
Background
Resistance to β-lactam antibiotics in Gram-negative bacte-
ria is a significant clinical problem in the community,
long-term care, and hospital settings [1-3]. In the com-
mon Gram-negative bacteria that are responsible for most
clinical infections, β-lactam resistance results from pro-
duction of penicillinases (predominantly the β-lactama-
ses designated TEM-1 and SHV-1), cephalosporinases
(e.g., extended-spectrum β-lactamases, ESBL, of TEM-,
SHV- and CTX-M-types), and the chromosomally or plas-
mid encoded AmpC enzymes [1]. Hence, an aggressive
search for novel therapeutic agents and rapid, accurate
detection methods is necessary.
Polymerase chain reaction (PCR) based techniques (such
as multiplex PCR, real time PCR, DNA microarrays) and
DNA-DNA hybridization have been used with success to
detect  bla  genes in Gram-negative bacilli [4-10]. Most
recently, fluorescence in situ hybridization (FISH) using
rRNA oligonucleotides has also been employed to detect
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β-lactamase genes [11,12]. Unfortunately, not all clinical
microbiology laboratories can perform the above molecu-
lar techniques. Even if available, these methodologies are
not routinely used to study clinical samples because they
are expensive and time consuming. We would also
emphasize that a PCR amplification product indicates the
presence of the gene only and does not always indicate
protein production.
In a previous study, our laboratory raised and character-
ized polyclonal antibodies against the SHV-1 β-lactamase
[13,14]. Immunogenic epitope mapping of the SHV β-
lactamase was reported. The polyclonal antibodies
detected as little as 1 ng of β-lactamase by immunoblot-
ting and pg quantities by enzyme-linked immunosorbent
assay (ELISA). Notably, cross reaction with other class A β-
lactamases (i.e., TEM- and CMY-2-like enzymes) was not
observed [13,14].
In this report, we extend our investigations and describe a
method using fluorescein-labeled polyclonal antibodies
(FLABs) to visualize the SHV-type β-lactamases expressed
in a laboratory strain of Escherichia coli and in a clinical
isolate of Klebsiella pneumoniae. With this technique, we
have developed a new method by which we could rapidly
detect SHV-type β-lactamases in clinical samples using
FLABs and fluorescence microscopy.
Methods
The SHV-1 β-lactamase gene was sub-cloned into the pBC
SK(-) vector (Stratagene, LaJolla, CA) from a clinical strain
of K. pneumoniae (15571), and transformed into E. coli
DH10B cells (Invitrogen, Carlsbad, CA) [15]. The K. pneu-
moniae clinical isolate possessed the SHV-5 ESBL and was
obtained from a previous study [16]. E. coli DH10B with-
out the blaSHV-1 gene served as a negative control.
The procedures used to isolate, express and purify the
SHV-1 β-lactamase and to produce the anti-SHV β-lacta-
mase antibodies have been previously detailed [13]. Puri-
fied anti-SHV antibodies were fluorescein-labeled with
the EZ-Label™ fluorescent labeling kit (Pierce, Rockford,
IL), according to the instructions of the manufacturer. In
brief, 1 mg of polyclonal anti-SHV antibodies in 1 ml
phosphate buffered saline (PBS, 2 mM monobasic
sodium phosphate, 8 mM dibasic sodium phosphate, 154
mM sodium chloride, pH 7.4) was mixed with 7.6 μl of a
10 mg/ml solution of NHS-fluorescein in N, N-dimethyl-
formamide for 1 hr at room temperature. A desalting col-
umn was then used to separate unbound fluorescein from
labeled antibodies. Labeled antibodies exiting the column
were monitored by measuring the absorbance of the sam-
ples at 280 nm. Then, the labeled antibodies were filter-
sterilized, protein concentration determined, and stored
at 4°C.
E. coli DH10B with and without the blaSHV-1 gene in the
pBC SK(-) phagemid vector and the clinical isolate of K.
pneumoniae possessing the SHV-5 β-lactamase were pre-
pared for staining and visualization by fluorescence
microscopy on a Zeiss Axiovert 200 inverted scope. Sta-
tionary phase cells were grown to 37°C in Luria Bertani
broth supplemented with either 20 μg/ml of chloram-
phenicol (Sigma, St. Louis, MO) or 50 μg/ml ampicillin
(Sigma), for E. coli DH10B harboring the blaSHV-1 gene or
the clinical isolate of K. pneumoniae, respectively. Antibi-
otics were not used in the case of E. coli DH10B cells
alone. Overnight cultures were diluted to an OD600 nm of
0.5 and 500 μl of cells were spun down and re-suspended
in 500 μl of 50 mM Tris HCl, pH 7.4. Lysozyme was added
to a final concentration of 1 mg/ml for 5 min, followed by
addition of 1 mM EDTA for 5 min. Cells were then pel-
leted (5000 g × 5 min), washed twice with PBS, and re-sus-
pended in 500 μl of PBS. Cells were fixed with the
addition of 100 μl of fixation buffer containing 200 mM
dibasic sodium phosphate, 0.3% glutaraldehyde, and 2%
formaldehyde (Sigma). Cells were incubated for 10 min at
room temperature and then for 45 min on ice, washed
once with PBS, and re-suspended in 250 μl PBS. Ten μl of
this suspension was placed on a poly-L-lysine coated slide
(Sigma), and after 1 min the liquid was aspirated off. The
adhered cells were gently washed once with 50 μl of PBS
and then the specimen was allowed to dry completely.
The fixation procedure was followed by re-hydration and
staining. Each cell-adhered area was re-hydrated by add-
ing 100 μl of PBS for 4 min followed by aspiration. Each
area was then blocked with 2% bovine serum albumin
(BSA), in PBS for 15 min at room temperature in a humid-
ity chamber, followed by aspiration. A 5 μg/ml solution of
FLABs in 2% BSA in PBS was then added and allowed to
incubate for 2 hrs in the humidity chamber. The cells were
then washed 10 times with PBS, the excess liquid was aspi-
rated off, and 2–3 drops of Gelmount was added followed
by the addition of a coverslip. The procedure aimed for a
fluorescence signal sufficient for imaging directly. The
Zeiss Axiovert 200 inverted scope was equipped with an
Axiocam digital microscope camera to capture immun-
ofluorescence images.
Results and discussion
Figure 1 demonstrates the immunofluorescence images
obtained using the fluorescence microscope at 1000 ×
total magnification. Figure 1a and 1b show E. coli DH10B
cells devoid of SHV β-lactamase stained with anti-SHV
FLABs. In Figure 1c and 1d we reveal the ability of anti-
SHV FLABs to detect periplasmic SHV β-lactamases in a
clinical  K. pneumoniae isolate expressing the SHV-5 β-
lactamase. Figure 1e and 1f demonstrate the visualization
of SHV-1 β-lactamase in a laboratory strain of E. coli
encoding and expressing SHV-1. In both instances, theBMC Microbiology 2009, 9:46 http://www.biomedcentral.com/1471-2180/9/46
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FLABs readily detected the SHV β-lactamases. It is also
noteworthy that this imaging technique reveals the mor-
phology of the isolates with great definition.
Although PCR amplification remains the "gold standard"
for the identification of blaSHV and other bla genes, FLABs
may prove to be a rapid and easy "bench top" method.
Our technique could be developed and used to rapidly
test clinically important samples (e.g., blood and sputum)
in a microbiology laboratory where the use of molecular
methods (e.g., PCR/sequencing) is less feasible. By exten-
sion, interest will also be keen to assess the presence, dis-
tribution and regulation of β-lactamase expression in
biofilms in device-associated infections.
When employing the FLABs method for β-lactamase
detection, three important caveats should be kept in
mind. Firstly, FLABs cannot distinguish between narrow-
spectrum (e.g., SHV-1), broad-spectrum (e.g., SHV-11),
and ESBLs (e.g., SHV-5 and SHV-12). Nevertheless, for
Gram-negative organisms that do not express chromo-
somal SHV-type β-lactamases (e.g., E. coli, Proteus spp.,
Enterobacter  spp.), evidence of SHV-type production is
often associated with ESBLs. In this case, rapid identifica-
tion of SHV enzymes could temper the use of cepha-
losporins and suggest an alternative antibiotic (e.g.,
carbapenems) in the critically ill patient with a serious
infection. Secondly, low level β-lactamase expression due
to either promoter mutations or gene copy number may
affect the ability of FLABs to detect these enzymes. How-
ever, it has been shown that the limit of detection/sensi-
tivity in ELISA experiments is at pg levels [13]. Thirdly,
FLABs may cross react and detect the homologous LEN-
type enzyme (possessed by some K. pneumoniae). In this
study we were not able to rule out the possibility of cross-
reaction between our FLABs and the LEN-type enzymes
because we do not possess a highly-purified LEN-type β-
lactamase and/or an isolate producing the blaLEN gene
a and b: E. coli DH10B cells devoid of SHV β-lactamase stained with anti-SHV FLABs Figure 1
a and b: E. coli DH10B cells devoid of SHV β-lactamase stained with anti-SHV FLABs. c and d: detection of peri-
plasmic SHV β-lactamase in a K. pneumoniae clinical isolate possessing the SHV-5 β-lactamase. e and f: visualization of SHV-1 β-
lactamase in a laboratory strain of E. coli expressing SHV-1. Microscopic magnification is 1000×. Figure 1b, 1d, and 1f are 
enlarged images.BMC Microbiology 2009, 9:46 http://www.biomedcentral.com/1471-2180/9/46
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alone. Based on a comparison of amino acids sequences
of SHV-1 and LEN-1 enzymes a homology of 90% was
observed. We compared the immunogenic epitopes of
SHV-1 to the amino acid sequence of LEN-1 [14]: the
most higly recognized epitope showed 100% identity
with the amino acid sequence of SHV-1 (data not shown).
Therefore, it is possible that the LEN-type β-lactamase
could be detected by our FLABs.
Conclusion
We developed a rapid and accurate method of visualizing
the SHV family of enzymes in clinical samples containing
Gram-negative bacilli using fluorescein-labeled polyclo-
nal antibodies. It has not escaped our attention that this
approach can also be applied to other β-lactamase types
and for different Gram-negative species. The application
of this methodology for clinical samples could help to
rapidly identify SHV production and promptly imple-
ment a more appropriate antibiotic therapy improving
clinical outcome (e.g., length of hospital stay and mortal-
ity) of patients with serious infections due to different
Gram-negative bacilli. The development of specific mon-
oclonal antibodies would ensure more widespread appli-
cation and supply. Further studies are planned to
determine the ability of this method to detect SHV β-lacta-
mase in a wide range of clinical isolates and to assess the
localization of β-lactamases within the cell [17].
Abbreviations
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